A first-of-its-kind, patent-pending, cancer-specific, Ōmics-based insurance policy, designed to provide invaluable resources to patients and their physicians.
A new approach to cancer management
Because detecting cancers at an early stage versus a late stage has a dramatic impact on survivability and associated healthcare costs.
Five-year relative survival for early-stage cancers is 91.1% compared to 30.6% for late-stage cancers.(5)
All cancers are the result of a genetic alteration.
How is cancer best treated?
By understanding if you inherited any known cancer-causing genes.
And by pairing the specific gene mutations in your cancer with targeted, precision treatments.
An end-to-end solution
All the important stuff in one policy – the most comprehensive cancer insurance product on the market
healthŌme One™ Heritable Cancer Risk Screening Test
Clinical-grade testing of 33 different inherited genes known to increase cancer risk. Genetic counseling and action plan if you have an above-average risk of developing cancer.
Precision Cancer Management
Comprehensive genomic profiling with expert medical review culminating in a precision treatment recommendation report for your oncologist. A dedicated oncology nurse navigator will help with health system navigation.
Cash payouts upon diagnosis to ease the financial burdens a cancer diagnosis often brings.
DNA-based Recurrence Monitoring (blood-based genetic test), continuing support from your oncology nurse advocate.
cancerŌme™ enhances and complements your health insurance and provides invaluable cancer resources to optimize treatment plan and recovery.
Incorporating cancerŌme™ into your existing critical illness or life insurance policies dramatically increases policyholder value and engagement.
cancerŌme™ provides genuine value to your clients and is a strong product differentiator. Enhance your offering with cancerŌme™.